Local Infiltration Analgesia Following Total Knee Arthroplasty (RAK-total)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary aim of this study is to evaluate if intra- and postoperative administration of ropivacaine, ketorolac and epinephrine into the operating field would affect morphine consumption. Secondary end-points are hospital stay, pain intensity and side effects. In an attempt to assess the safety of this technique, knee function and patient satisfaction scores are assessed up to 3 months after surgery.
| Condition | Intervention |
|---|---|
|
Postoperative Pain |
Drug: ropivacaine, ketorolac and epinephrine Drug: saline |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Local Infiltration Analgesia With Ropivacaine, Ketorolac and Epinephrine Intra- and Postoperatively in Total Knee Arthroplasty |
- Morphine consumption [ Time Frame: 0-48 hours ] [ Designated as safety issue: No ]
- hospital stay, pain intensity, side effects, knee function and patient satisfaction scores [ Time Frame: 0-3 months ] [ Designated as safety issue: No ]
| Enrollment: | 48 |
| Study Start Date: | April 2007 |
| Study Completion Date: | September 2008 |
| Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1 Group A(Active)
Group A (Active) receives a multimodal injection intra- and postoperatively
|
Drug: ropivacaine, ketorolac and epinephrine
In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
|
|
Placebo Comparator: 2 Group P (Placebo)
Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
|
Drug: saline
In Group P (placebo) no injections were given intraoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
|
Detailed Description:
Postoperative pain is often severe following knee arthroplasty. Recently, a local infiltration analgesia (LIA) technique was developed by Drs Kerr and Kohan in Sydney, Australia. With this LIA-technique, a long-acting local anesthetic (ropivacaine), a nonsteroidal anti-inflammatory drug (ketorolac), and epinephrine are infiltrated intraoperatively and via an intraarticular catheter postoperatively. We ahve completed a study on unicompartmental knee arthroplasty and the present study is investigating total knee arthroplasties.
The primary aim of this study is to evaluate if intra- and postoperative administration of ropivacaine, ketorolac and epinephrine into the operating field would affect morphine consumption. Secondary end-points are hospital stay, pain intensity and side effects. In an attempt to assess the safety of this technique, knee function and patient satisfaction scores are assessed up to 3 months after surgery.
Eligibility| Ages Eligible for Study: | 20 Years to 85 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients scheduled for total knee arthroplasty
- Aged 20-85 yrs
- ASA physical status I-III and mobility indicating normal postoperative mobilization
Exclusion Criteria:
- Known allergy or intolerance to one of the study drugs
- Serious liver-, heart- or renal decease
- Rheumatoid arthritis
- Chronic pain or bleeding disorder
Contacts and Locations| Sweden | |
| University Hospital Orebro | |
| Orebro, Sweden, 701 85 | |
| University Hospital Orebro | |
| Orebro, Sweden, 70185 | |
| Principal Investigator: | Kjell Axelsson, Prof | University Hospital Orebro, Sweden |
More Information
No publications provided
| Responsible Party: | Kjell Axelsson, Prof, University Hospital Orebro, Orebro, Sweden |
| ClinicalTrials.gov Identifier: | NCT00799175 History of Changes |
| Other Study ID Numbers: | RAK-total |
| Study First Received: | November 26, 2008 |
| Last Updated: | November 26, 2008 |
| Health Authority: | Sweden: Medical Products Agency |
Keywords provided by University Hospital Orebro:
|
Postoperative pain Local infiltration analgesia Knee arthroplasty |
Additional relevant MeSH terms:
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Signs and Symptoms Epinephrine Epinephryl borate Ketorolac Ketorolac Tromethamine Ropivacaine Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Physiological Effects of Drugs Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses Mydriatics Adrenergic alpha-Agonists Sympathomimetics Vasoconstrictor Agents Cardiovascular Agents Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic |
ClinicalTrials.gov processed this record on May 22, 2013